These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34622175)

  • 41. Pilot-scale production of inactivated monoglycosylated split H
    Wu CY; Kao SE; Tseng YC; Lin YP; Hou JT; Wu LY; Chiu S; Ma CA; Hsiao PW; Hsiao J; Chen JR
    Antiviral Res; 2023 Aug; 216():105640. PubMed ID: 37263355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.
    Khodai T; Chappell D; Christy C; Cockle P; Eyles J; Hammond D; Gore K; McCluskie MJ; Evans DM; Lang S; Loudon PT; Townend T; Wright P; West K; Bright H
    Clin Vaccine Immunol; 2011 Oct; 18(10):1702-9. PubMed ID: 21852545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influenza virus-like particles containing M2 induce broadly cross protective immunity.
    Song JM; Wang BZ; Park KM; Van Rooijen N; Quan FS; Kim MC; Jin HT; Pekosz A; Compans RW; Kang SM
    PLoS One; 2011 Jan; 6(1):e14538. PubMed ID: 21267073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine.
    Li J; Arévalo MT; Chen Y; Chen S; Zeng M
    Int J Infect Dis; 2014 Oct; 27():37-43. PubMed ID: 25172265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
    Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
    Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components.
    Hernandez-Davies JE; Felgner J; Strohmeier S; Pone EJ; Jain A; Jan S; Nakajima R; Jasinskas A; Strahsburger E; Krammer F; Felgner PL; Davies DH
    Front Immunol; 2021; 12():692151. PubMed ID: 34335601
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice.
    Nguyen HH; van Ginkel FW; Vu HL; Novak MJ; McGhee JR; Mestecky J
    J Virol; 2000 Jun; 74(12):5495-501. PubMed ID: 10823854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Comparison Between Recombinant
    Teran-Navarro H; Salcines-Cuevas D; Calderon-Gonzalez R; Tobes R; Calvo-Montes J; Pérez-Del Molino Bernal IC; Yañez-Diaz S; Fresno M; Alvarez-Dominguez C
    Front Immunol; 2021; 12():632304. PubMed ID: 33953709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice.
    He W; Chen CJ; Mullarkey CE; Hamilton JR; Wong CK; Leon PE; Uccellini MB; Chromikova V; Henry C; Hoffman KW; Lim JK; Wilson PC; Miller MS; Krammer F; Palese P; Tan GS
    Nat Commun; 2017 Oct; 8(1):846. PubMed ID: 29018261
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
    Ann J; Samant M; Rheaume C; Dumas C; Beaulieu E; Morasse A; Mallett C; Hamelin ME; Papadopoulou B; Boivin G
    Vaccine; 2014 Sep; 32(43):5730-9. PubMed ID: 25173481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes.
    Liao HY; Wang SC; Ko YA; Lin KI; Ma C; Cheng TR; Wong CH
    Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17757-17763. PubMed ID: 32669430
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant.
    Luo J; Liu XP; Xiong FF; Gao FX; Yi YL; Zhang M; Chen Z; Tan WS
    Front Immunol; 2019; 10():2274. PubMed ID: 31611875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Partial Protection against Porcine Influenza A Virus by a Hemagglutinin-Expressing Virus Replicon Particle Vaccine in the Absence of Neutralizing Antibodies.
    Ricklin ME; Vielle NJ; Python S; Brechbühl D; Zumkehr B; Posthaus H; Zimmer G; Summerfield A
    Front Immunol; 2016; 7():253. PubMed ID: 27446083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection.
    Lee YN; Kim MC; Lee YT; Hwang HS; Cho MK; Lee JS; Ko EJ; Kwon YM; Kang SM
    Vaccine; 2014 Jul; 32(35):4578-4585. PubMed ID: 24951867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
    Yu H; Jiang X; Shen C; Karunakaran KP; Jiang J; Rosin NL; Brunham RC
    Infect Immun; 2010 May; 78(5):2272-82. PubMed ID: 20231405
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
    Ni Y; Guo J; Turner D; Tizard I
    Front Immunol; 2018; 9():1815. PubMed ID: 30140267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Seasonal Influenza Split Vaccines Confer Partial Cross-Protection against Heterologous Influenza Virus in Ferrets When Combined with the CAF01 Adjuvant.
    Christensen D; Christensen JP; Korsholm KS; Isling LK; Erneholm K; Thomsen AR; Andersen P
    Front Immunol; 2017; 8():1928. PubMed ID: 29358939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.